Imidazoles and benzimidazoles as putative inhibitors of SARS-CoV-2 B.1.1.7 (Alpha) and P.1 (Gamma) variant spike glycoproteins: A computational approach
- 18 October 2021
- journal article
- research article
- Published by Springer Nature in Chemical Papers
- Vol. 76 (2) , 1107-1117
Abstract
COVID-19 is an unprecedented pandemic threatening global health, and variants were discovered rapidly after the pandemic. The two variants, namely the SARS-CoV-2 B.1.1.7 (Alpha) and P.1 (Gamma), were formed by the mutations in the receptor binding domain of spike glycoprotein (SGP). These two variants are known to possess a high binding affinity with the angiotensin-converting enzyme 2. Amidst the rapid spread of these mutant strains, research and development of novel molecules become tedious and labour-intensive. Imidazole and benzimidazole scaffolds were selected in this study based on their unique structural features and electron-rich environment, resulting in increased affinity against a variety of therapeutic targets. In the current study, imidazole- and benzimidazole-based anti-parasitic drugs are repurposed against SARS-CoV-2 Alpha and Gamma variant spike glycoproteins using computational strategies. Out of the screened 15 molecules, flubendazole and mebendazole have exhibited promising binding features to the two receptors (PDB ID: 7NEH and 7NXC), as evidenced by their glide score and binding free energy. The results are compared with that of the two standard drugs, remdesivir and hydroxychloroquine. Flubendazole and mebendazole have become convenient treatment options against mutant lineages of SARS-CoV-2. The edge of the flubendazole was further established by its stability in MD simulation conducted for 100 ns employing GROMACS software. Further, in vitro and in vivo studies are essential to understand, if flubendazole and mebendazole indeed hold the promise to manage SARS-CoV-2 mutant stains. Graphic abstractKeywords
This publication has 35 references indexed in Scilit:
- The VSGB 2.0 model: A next generation energy model for high resolution protein structure modelingProteins: Structure, Function, and Bioinformatics, 2011
- Synthesis and pharmacological evaluation of novel 5-substituted-1-(phenylsulfonyl)-2-methylbenzimidazole derivatives as anti-inflammatory and analgesic agentsEuropean Journal of Medicinal Chemistry, 2010
- Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand ComplexesJournal of Medicinal Chemistry, 2006
- PRODRG: a tool for high-throughput crystallography of protein–ligand complexesActa Crystallographica Section D Structural Biology, 2004
- The Polar Hydrophobicity of Fluorinated CompoundsChemBioChem, 2004
- A hierarchical approach to all‐atom protein loop predictionProteins: Structure, Function, and Bioinformatics, 2004
- Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database ScreeningJournal of Medicinal Chemistry, 2004
- Accelerated Poisson–Boltzmann calculations for static and dynamic systemsJournal of Computational Chemistry, 2002
- Molecular dynamics with coupling to an external bathThe Journal of Chemical Physics, 1984
- The Chemistry of the Benzimidazoles.Chemical Reviews, 1951